SCHEMBL4635262

SCHEMBL4635262

Cc1c(S(=O)(=O)c2ccc(F)cc2)c2ccccn2c1CC(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 3/20 0.55
HCRTR2 O43614 3/20 0.55
PTGDR2 Q9Y5Y4 10/20 0.51
PTGDR Q13258 3/20 0.51
CYP2C9 P11712 2/20 0.51
CYP3A4 P08684 1/20 0.51
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44
MMP3 P08254 1/20 0.44
MMP9 P14780 1/20 0.44
MMP12 P39900 1/20 0.44
MMP13 P45452 1/20 0.44
MMP14 P50281 1/20 0.44
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
ALDH1A1 P00352 2/20 0.43
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
HTR6 P50406 1/20 0.41
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2584567 0.92 HCRTR1 (0.52) HCRTR1HCRTR2PTGDR2PTGDRCYP2C9
SCHEMBL4635639 0.88 HCRTR1 (0.47) HCRTR1HCRTR2PTGDR2PTGDRCYP2C9
SCHEMBL4635636 0.88 HCRTR1 (0.52) HCRTR1HCRTR2PTGDR2PTGDRCYP2C9
SCHEMBL2594270 0.84 HCRTR2 (0.75) HCRTR1HCRTR2PTGDR2PTGDRCYP2C9
SCHEMBL2585096 0.77 HCRTR2 (0.74) HCRTR1HCRTR2PTGDR2PTGDRCYP2C9
SCHEMBL2584748 0.77 HCRTR2 (0.63) HCRTR1HCRTR2PTGDR2PTGDRCYP2C9
SCHEMBL4636277 0.76 HCRTR1 (0.43) HCRTR1HCRTR2PTGDR2MEN1KMT2A
SCHEMBL4636242 0.75 MAPT (0.45) HCRTR1HCRTR2MEN1KMT2AALDH1A1
SCHEMBL4635350 0.74 HTR6 (0.41) HCRTR1HCRTR2CYP3A4MEN1KMT2A
SCHEMBL2588741 0.73 HCRTR2 (0.71) HCRTR1HCRTR2MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306109-A1 Indolizine Derivatives as Ligands of the Crth2 Receptor ARGENTA DISCOVERY LIMITED (GB) 2008-12-11 US disclosed
US-20080306109-A1 Indolizine Derivatives as Ligands of the Crth2 Receptor ARGENTA DISCOVERY LIMITED (GB) 2008-12-11 US disclosed
US-20080306109-A1 Indolizine Derivatives as Ligands of the Crth2 Receptor ARGENTA DISCOVERY LIMITED (GB) 2008-12-11 US disclosed
EP-1931663-A1 IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR Argenta Discovery Limited (GB) 2008-06-18 EP disclosed
WO-2007031747-A1 IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR ARGENTA DISCOVERY LIMITED (GB) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306109-A1 Indolizine Derivatives as Ligands of the Crth2 Receptor HRH4, HRH2, HRH3 HCRTR1 32/4885HCRTR2 7/4885PTGDR2 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.